Specifications
setting
Stability
assessment
Cleaning validation
Parallel development of analytical methods
Interchangeability (IC)
Interchangeability (IC) of multisource generic FPPs
(Essential similarity with Innovator FPP)
Pharmaceutical + Bioequivalence
Equivalence
IC = PE + BE
Training Workshop on Pharmaceutical Development
|
3 with a Focus on Paediatric Medicines / 15-19 October 2007
Pharmaceutical equivalence
FPPs meet the same or comparable standards
Equivalence in stability
Equivalence in manufacture (WHO-GMP)
Training Workshop on Pharmaceutical Development
|
4 with a Focus on Paediatric Medicines / 15-19 October 2007
Prequalification requirements
Validation of analytical methods is a prerequisite for
prequalification of product dossiers
Non-compendial APIs and FPPs are tested with methods
developed by the manufacturer
For compendial APIs and FPPs the applicability of
methods to particular products must be demonstrated
(verification)
PHARMACEUTICAL
METHODS
enable by suitable
surroundings
Management
Training Workshop on Pharmaceutical Development
|
7 with a Focus on Paediatric Medicines / 15-19 October 2007
Validation characteristics
Identification
Impurities
quantitative
limit
Assay
Accuracy
Precision
Specificity
Detection Limit
Quantitation Limit
Linearity
Range
Robustness
Accurate
&
precise
Accurate
&
imprecise
Inaccurate
&
precise
Precision
Expresses the closeness of agreement between a series
of measurements obtained from multiple sampling of the
same homogenous sample
Is usually expressed as the standard deviation (S),
variance (S2) or coefficient of variation (RSD) of a series
of measurements
Precision may be considered at three levels
Repeatability (intra-assay precision)
Intermediate Precision (variability within a laboratory)
Reproducibility (precision between laboratories)
Training Workshop on Pharmaceutical Development
|
10 with a Focus on Paediatric Medicines / 15-19 October 2007
General consideration
68.26% of measured values
within mean 1 SD
95.46% of measured values
within mean 2 SD
99.73% of measured values
within mean 3 SD
An interval of 3 SD should
be calculated to fully cover variability
Training Workshop on Pharmaceutical Development
|
11 with a Focus on Paediatric Medicines / 15-19 October 2007
Mean
Spread of data
1SD
2SD
3SD
Repeatability
Determination of the API in a FPP (tablet):
Six replicate sample preparation steps from a homogenously prepared tablet
mixture (nominal value of API 150 mg)
Injection Peak area Assay
1
173865
147.10 mg/98.06%
174926
148.00 mg/98.66%
172933
146.32 mg/97.54%
175011
148.08 mg/98.72%
179557
151.95 mg/101.30%
176425
149.28 mg/99.52%
Mean
175453
148.45 mg/98.96%
SD
2329
1.98 mg/1.32%
RSD
1.32%
1.32%
Mean 3 SD =
Confidence interval of 99.73%
98.96 3x1.32% = 95% - 102.92%
Intermediate Precision
Expresses within-laboratories variations
Different days, different analysts, different equipment etc.
Injection
1
2
3
4
5
6
Mean
SD
RSD
Peak area
analyst 1
173865
174926
172933
175011
179557
176425
175453
2329
1.32%
Peak area
analyst 2
175656
175878
176004
176344
175332
174959
175695
495
0.28%
Peak area
analyst 3
177965
178556
177342
178011
179466
179688
178504
918
0.51%
Reproducibility
Expresses the precision between laboratories
Collaborative studies, usually applied to standardisation of
methodology
Transfer of technology
Compendial methods
Accuracy
Expresses the closeness of agreement between the value
which is accepted either as a conventional true value or
an accepted reference value and the value found
true
mean
Accuracy
To find out whether a method is accurate:
Drug substance (assay)
Application of the method to an analyte of known purity (e.g. reference
substance)
Comparison of the results of one method with those of a second wellcharacterised method (accuracy known)
Accuracy
Application of the method to synthetic mixtures of the drug product
component to which known quantities of the analyte have been
added
Recovery reduced
by ~10 15%
Specificity
Is the ability to assess unequivocally the analyte in the presence of
components which may be expected to be present (impurities,
degradants, matrix)
Identity testing
To ensure the identity of an analyte
Purity testing
To ensure accurate statement on the content of impurities of an analyte
Assay
To allow an accurate statement on the content of an analyte in a sample
Specificity
Overlay chromatogram of an impurity solution with a sample solution
LOD/LOQ
LOD, LOQ and Signal to Noise Ratio (SNR)
LOQ
LOD
Noise
Linearity
The linearity of an analytical procedure is its ability
(within a given range) to obtain test results which are
directly proportional to the concentration (amount) of
analyte in the sample
If there is a linear relationship test results should be
evaluated by appropriate statistical methods
Correlation coefficient (R2)
Y-intercept
Slope of regression line
Residual sum of squares
PLOT OF THE DATA
Training Workshop on Pharmaceutical Development
|
27 with a Focus on Paediatric Medicines / 15-19 October 2007
Linearity
Usual acceptance criteria for a linear calibration curve
r > 0.999; y-intercept a < 0 to 5% of target concentration; RSD response < 1.5-2%
Source: Analytical Method Validation and Instrument Performance Verification, Edited by Chung ChowChan, Herman Lam,
Y.C. Lee,and Xue-Ming ZhangISBN 0-471-25953-5 Wiley & Sons
Range
Range
Assay
80 to 120% of test concentration
Content uniformity
70 to 130% of test concentration)
Dissolution
Q-20% to 120%
Impurities
Reporting level 120% of specification limit (with respect to test
concentration of API)
Range
Linearity is limited to 150% of
shelf life specification of
impurities
Test concentration can be
used to determine impurities
To determine drug substance
(assay) the test concentration
must be diluted
The range is 0 ~ 150% of
impurity specification
Robustness
Robustness of an analytical procedure should show
the reliability of an analysis with respect to deliberate
variations in method parameters
The evaluation of robustness should be considered
during the development phase
If measurements are susceptible to variations in
analytical conditions the analytical conditions should
be suitably controlled or a precautionary statement
should be included in the procedure
Training Workshop on Pharmaceutical Development
|
32 with a Focus on Paediatric Medicines / 15-19 October 2007
Robustness
Influence of buffer pH and buffer concentration in mobile phase on
retention times of API and impurities
API
Impurity A
Impurity B
Impurity C
As is
10.46
3.86
7.43
8.26
buffer pH 5.9
10.45
3.94
7.51
8.38
buffer pH 6.9
10.46
3.94
7.49
8.34
7.84
3.43
6.16
6.66
15.26
4.77
9.61
11.18
Method stability
System suitability over time
Stability of analytical solutions
Sample solution stability
A solution of stavudine is stable for ~ 2 h, then it starts to degrade to
thymine
Impurity-spiked sample solution stability
Cave: A solution containing stavudine spiked with its impurity thymine
does not allow to clearly distinguish between degradation and spike due
to the lower precision at impurity levels
Should be analysed immediately
Training Workshop on Pharmaceutical Development
|
35 with a Focus on Paediatric Medicines / 15-19 October 2007
Setting Specifications
Upper and lower specification limits
Process variability
Analytical variability
3 SD and specification acceptance range
Summary
Analytical procedures play a critical role in
pharmaceutical equivalence and risk
assessment/management
Establishment of product-specific acceptance criteria
Assessment of stability of APIs and FPPs
THANK YOU